PCa Commentary | Volume 166 – June 2022
This Commentary looks at developing research on how to use CAR-T cell immunotherapy to treat prostate cancer.
Read MoreSelect Page
Edward Weber, MD, is a retired medical oncologist living in Seattle, Washington. He was born and raised in a suburb of Reading, Pennsylvania. After graduating from Princeton University in 1956 with a BA in History, Dr. Weber attended medical school at the University of Pennsylvania. His internship training took place at the University of Vermont in Burlington.
A tour of service as a Naval Flight Surgeon positioned him on Whidbey Island, Washington, and this introduction to the Pacific Northwest ultimately proved irresistible. Following naval service, he received postgraduate training in internal medicine in Philadelphia at the Pennsylvania Hospital and then pursued a fellowship in hematology and oncology at the University of Washington.
His career in medical oncology was at the Tumor Institute of the Swedish Hospital in Seattle where his practice focused largely on the treatment of patients experiencing lung, breast, colon, and genitourinary cancer and malignant lymphoma.
Toward the end of his career, he developed a particular concentration on the treatment of prostate cancer. Since retirement in 2002, he has authored the PCa Commentary, published by the Prostate Cancer Treatment Research Foundation, an analysis of new developments in the prostate cancer field with essays discussing and evaluating treatment management options in this disease. He is a regular speaker at various prostate cancer support groups around Seattle.
Posted by Edward Weber, MD | Jun 2022
This Commentary looks at developing research on how to use CAR-T cell immunotherapy to treat prostate cancer.
Read MorePosted by Edward Weber, MD | May 2022
This Commentary looks at Lutetium-177 PSMA-617 therapy radioligand therapy for metastatic castration-resistant prostate cancer.
Read MorePosted by Edward Weber, MD | Apr 2022
This Commentary looks at an emerging management trifecta for recurrent prostate cancer: PSMA PET, oligometastatic cancer & focal therapy.
Read MorePosted by Edward Weber, MD | Mar 2022
This Commentary looks at how the Decipher assay assists in decision-making for how to treat patients with prostate cancer.
Read MorePosted by Edward Weber, MD | Feb 2022
This Commentary gives an update on patient selection and monitoring for prostate cancer active surveillance.
Read More